NCT02954874 2026-03-17Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast CancerNational Cancer Institute (NCI)Phase 3 Active not recruiting1,155 enrolled
NCT03418961 2025-10-08S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac ToxicitySWOG Cancer Research NetworkPhase 3 Recruiting491 enrolled